Literature DB >> 10398159

Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid.

S Scarpino1, A Stoppacciaro, C Pellegrini, A Marzullo, L Zardi, F Tartaglia, G Viale, L P Ruco.   

Abstract

Cellular fibronectins containing the extracellular domain A or B (EDA and EDB) are particularly abundant in fetal and neoplastic tissues. The presence of EDA and EDB was investigated in 28 cases of papillary carcinoma of the thyroid using IST-9 and BC-1 monoclonal antibodies. Immunostaining for EDA and EDB was detected in tumour stroma, in tumour basement membranes, and in tumour blood vessels. EDA was present in 27 of the 28 cases, in 20 of which more than 75 per cent of the tumour stroma was stained. Immunostaining for EDB was detected in 23 of the 28 cases and was less pronounced than that for EDA, being present in less than 25 per cent of the tumour stroma in most cases. Reactivity for EDA/EDB was not observed in the adjacent normal thyroid in any of the cases investigated. In a group of 20 non-papillary tumours, immunostaining for EDA was present in the stroma of three follicular carcinomas (one minimally and two widely invasive), one medullary carcinoma, and 5 of 16 follicular adenomas; expression of EDB was more restricted, being present in only the two cases of widely invasive follicular carcinoma. The presence of EDA and EDB was not correlated with the extent of fibrosis or the degree of tumour cell differentiation. Immunoreactivity was already present in microcarcinomas. These observations raise the possibility that the production of oncofetal fibronectins is an important step in papillary carcinoma tumourigenesis, perhaps facilitating adhesion and spreading of tumour cells. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398159     DOI: 10.1002/(SICI)1096-9896(199906)188:2<163::AID-PATH335>3.0.CO;2-1

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.

Authors:  Zheng Han; Han Cheng; Jenny G Parvani; Zhuxian Zhou; Zheng-Rong Lu
Journal:  Magn Reson Med       Date:  2017-10-29       Impact factor: 4.668

2.  Synthesis and assessment of ZD2-(68Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer.

Authors:  Songqi Gao; Jingcan Qin; Olga Sergeeva; Maxim Sergeev; Peter Qiao; Sarah Roelle; Norbert Avril; Zhenghong Lee; Yajuan Li; Zhengrong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

3.  Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors.

Authors:  Francois Bordeleau; Joseph P Califano; Yashira L Negrón Abril; Brooke N Mason; Danielle J LaValley; Sandra J Shin; Robert S Weiss; Cynthia A Reinhart-King
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-23       Impact factor: 11.205

4.  Fibronectin splice variation in human knee cartilage, meniscus and synovial membrane: observations in osteoarthritic knee.

Authors:  Carla R Scanzello; Dessislava Z Markova; Ana Chee; Yan Xiu; Sherrill L Adams; Greg Anderson; Miltiadis Zgonis; Ling Qin; Howard S An; Yejia Zhang
Journal:  J Orthop Res       Date:  2015-01-06       Impact factor: 3.494

5.  Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis.

Authors:  J Kriegsmann; A Berndt; T Hansen; L Borsi; L Zardi; R Bräuer; P K Petrow; M Otto; C J Kirkpatrick; S Gay; H Kosmehl
Journal:  Rheumatol Int       Date:  2003-04-24       Impact factor: 2.631

6.  Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis.

Authors:  Sophie Astrof; Denise Crowley; Elizabeth L George; Tomohiko Fukuda; Kiyotoshi Sekiguchi; Douglas Hanahan; Richard O Hynes
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 7.  Fibronectins in vascular morphogenesis.

Authors:  Sophie Astrof; Richard O Hynes
Journal:  Angiogenesis       Date:  2009-02-14       Impact factor: 9.596

Review 8.  The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid.

Authors:  Luigi Ruco; Stefania Scarpino
Journal:  Biomedicines       Date:  2014-10-24

Review 9.  Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.

Authors:  Ana Cavaco; Maryam Rezaei; Stephan Niland; Johannes A Eble
Journal:  Int J Mol Sci       Date:  2017-11-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.